Iovance Biotherapeutics Inc (NASDAQ: IOVA) is 18.82% higher on its value in year-to-date trading and has touched a low of $3.21 and a high of $18.33 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The IOVA stock was last observed hovering at around $10.15 in the last trading session, with the day’s loss setting it -0.49%.
Currently trading at $9.66, the stock is -8.19% and -1.10% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.04 million and changing -4.83% at the moment leaves the stock -6.58% off its SMA200. IOVA registered 91.86% gain for a year compared to 6-month loss of -35.69%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -16.87% gain in the last 1 month and extending the period to 3 months gives it a 18.38%, and is -1.53% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.84% over the week and 6.41% over the month.
Iovance Biotherapeutics Inc (IOVA) has around 557 employees, a market worth around $2.93B and $32.77M in sales. Profit margin for the company is -1343.27%. Distance from 52-week low is 200.93% and -47.30% from its 52-week high. The company has generated returns on investments over the last 12 months (-52.48%).
The EPS is expected to grow by 31.97% this year.
Iovance Biotherapeutics Inc (IOVA) Top Institutional Holders
394.0 institutions hold shares in Iovance Biotherapeutics Inc (IOVA), with institutional investors hold 87.93% of the company’s shares. The shares outstanding are 256.14M, and float is at 247.13M with Short Float at 23.34%. Institutions hold 87.47% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 25.95 million shares valued at $208.12 million. The investor’s holdings represent 9.7478% of the IOVA Shares outstanding. As of 2024-06-30, the second largest holder is PERCEPTIVE ADVISORS LLC with 25.93 million shares valued at $207.98 million to account for 9.7412 of the shares outstanding. The other top investors are MHR FUND MANAGEMENT LLC which holds 24.0 million shares representing 9.014% and valued at over $192.46 million, while BLACKROCK INC. holds 7.9728 of the shares totaling 21.23 million with a market value of $170.23 million.
Iovance Biotherapeutics Inc (IOVA) Insider Activity
The most recent transaction is an insider purchase by MCPEAK MERRILL A, the company’s Director. SEC filings show that MCPEAK MERRILL A bought 250,000 shares of the company’s common stock on Feb 20 ’24 at a price of $9.15 per share for a total of $2.29 million. Following the purchase, the insider now owns 0.32 million shares.
Iovance Biotherapeutics Inc disclosed in a document filed with the SEC on Feb 20 ’24 that Dukes Iain D. (Director) bought a total of 32,000 shares of the company’s common stock. The trade occurred on Feb 20 ’24 and was made at $9.15 per share for $0.29 million. Following the transaction, the insider now directly holds 54000.0 shares of the IOVA stock.
Still, SEC filings show that on Feb 20 ’24, Rothbaum Wayne P. (Director) acquired 5,000,000 shares at an average price of $9.15 for $45.75 million. The insider now directly holds 28,067,333 shares of Iovance Biotherapeutics Inc (IOVA).
